Tag: cognitive decline

1. Early-life cognitive enrichment was associated with decreased Alzheimer’s disease pathology and cognitive decline in late-life. Evidence Rating Level: 2 (Good) Factors such as educational performance and childhood socioeconomic status impact cognitive decline and Alzheimer’s disease- (AD) related pathology later in life. While these are components of early-life cognitive enrichment (ECLE),...
1. Preclinical amyloid-β was associated with significant cognitive decline in clinically normal adults across screening and comprehensive measures. 2. Amyloid-β-positive individuals were more likely to carry at least one APOE ε4 allele and have a family history of dementia. Evidence Rating Level: 3 (Average) Amyloid-β (Aβ) pathology is known as the preclinical phase of...
1. Verubecestat, an orally administered beta amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor , did not slow or prevent the progression of dementia among patients with prodromal Alzheimer’s disease. 2. Adverse events were more often noted in the verubecestat groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prodromal Alzheimer’s disease...
1. In patients with mild Alzheimer’s disease solanezumab, an antibody designed to facilitate clearance of amyloid-beta plaques, did not significantly reduce cognitive decline over time. 2. There was no difference in overall rates of serious adverse events or death between the study and placebo arms of the trial. Evidence Rating Level:...
1. Physical activity interventions to prevent late-life dementia included aerobic exercise, resistance training, Tai Chi, and multidomain interventions. 2. There is insufficient evidence to draw conclusions as to the efficacy of physical activity with respect to preventing cognitive decline and dementia. Evidence Rating Level: 1 (Excellent) Study Rundown: Dementia is defined as...
1. Pharmacologic treatments had no impact on preventing late-life dementia in patients with normal cognition. 2. Adverse events were increased for several pharmacologic interventions aimed at reducing dementia risk. Evidence Rating Level: 1 (Excellent) Study Rundown: Dementia is a significant clinical syndrome, which affects a large proportion of the aging population. Dementia...
1. There was inadequate evidence that any over-the-counter (OTC) supplement helped to prevent or delay decline in cognition. 2. The authors recommend further research using larger scale trials and clinically important outcomes to examine the effects of OTC supplements on cognition. Evidence Rating Level: 1 (Excellent)    Study Rundown: Concerns about cognitive decline...
1. In healthy elderly adults, cognitive training enhanced cognitive performance in the area that was trained, but there did not seem to be any effect on adults with mild cognitive impairment (MCI). 2. There was inadequate evidence regarding prevention of dementia or decline in cognition through cognitive training. Evidence Rating Level:...
1. By comparing the baseline blood pressures and BP trends of elderly individuals with or without subcortical or cortical microinfarcts at autopsy, the authors identified an association between a steeper BP decline and the presence of subcortical microinfarcts. 2. Cortical microinfarcts were associated with the presence of the apolipoprotein E...
1. In this meta-analysis of available studies, prospective data demonstrated that sleep-disordered breathing (SDB) is associated with an increased risk of developing cognitive impairment. 2. Analysis of cross-sectional studies indicate that SDB is linked to worse executive functioning scores on assessment; with no associated deficits in memory or global cognition. Evidence...